Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2013

01.05.2013 | Original Article

Different Profile of Peripheral Antioxidant Enzymes and Lipid Peroxidation in Active and Non-active Inflammatory Bowel Disease Patients

verfasst von: D. Achitei, A. Ciobica, G. Balan, E. Gologan, C. Stanciu, G. Stefanescu

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The role of oxidative stress in inflammatory bowel diseases (IBD) has been extended lately from a simple consequence of inflammation to a potential etiological factor, but the data are still controversial. Active disease has been characterized before by an enhanced production of reactive oxygen species and the increased peroxidation of lipids, but patients in remission were generally not considered different from healthy people in terms of oxidative stress.

Aims

We evaluated the antioxidant defense capacity and lipid peroxidation status in the serum of patients with active and non-active disease compared with healthy matched control subjects.

Methods

The study included 20 patients with confirmed IBD in clinical and biological remission, 21 patients with active disease, and 18 controls. We determined the serum levels of two antioxidant enzymes, superoxide dismutase (SOD) and glutathione peroxidase (GPX), and a lipid peroxidation marker, malondialdehyde (MDA).

Results

Active disease patients had an increased activity of both SOD and GPX, as well as significant high values of MDA versus controls. Furthermore, patients being in remission had significantly lower values of antioxidant enzymes (SOD and GPX) and increased lipid peroxidation measured by MDA serum levels, as compared with healthy control subjects.

Conclusions

Our study confirmed the presence of high oxidative stress in active IBD. More importantly, we have demonstrated a lower antioxidant capacity of patients in remission versus control group. This may represent a risk factor for the disease and can be an additional argument for the direct implication of oxidative stress in the pathogenesis of IBD.
Literatur
1.
Zurück zum Zitat Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. New York: Oxford University Press; 2007. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. New York: Oxford University Press; 2007.
2.
Zurück zum Zitat Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis. 2012;18:1982–1996.PubMedCrossRef Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis. 2012;18:1982–1996.PubMedCrossRef
3.
Zurück zum Zitat Glocker E, Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency?. Cell Mol Life Sci. 2012;69:41–48.PubMedCrossRef Glocker E, Grimbacher B. Inflammatory bowel disease: is it a primary immunodeficiency?. Cell Mol Life Sci. 2012;69:41–48.PubMedCrossRef
4.
Zurück zum Zitat Harris ML, Schiller HJ, Reilly PM, et al. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease. Cause, consequence or epiphenoma ? Pharmacol Ther. 1992;53:375–408.PubMedCrossRef Harris ML, Schiller HJ, Reilly PM, et al. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease. Cause, consequence or epiphenoma ? Pharmacol Ther. 1992;53:375–408.PubMedCrossRef
5.
Zurück zum Zitat Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015–2021.PubMedCrossRef Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015–2021.PubMedCrossRef
6.
Zurück zum Zitat Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.PubMedCrossRef Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.PubMedCrossRef
7.
Zurück zum Zitat Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? Aliment Pharmacol Ther. 2002;16:1997–2015.PubMedCrossRef Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? Aliment Pharmacol Ther. 2002;16:1997–2015.PubMedCrossRef
8.
Zurück zum Zitat Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94.PubMedCrossRef Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94.PubMedCrossRef
9.
Zurück zum Zitat Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996;41:2078–2086.PubMedCrossRef Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996;41:2078–2086.PubMedCrossRef
10.
Zurück zum Zitat Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1433–1437.PubMedCrossRef Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1433–1437.PubMedCrossRef
11.
Zurück zum Zitat Kruidenier L, Kuiper I, Van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003;201:17–27.PubMedCrossRef Kruidenier L, Kuiper I, Van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003;201:17–27.PubMedCrossRef
12.
Zurück zum Zitat Durak I, Yasa MH, Bektas A, et al. Mucosal antioxidant defense is not impaired in ulcerative colitis. Hepatogastroenterology. 2000;47:1015–1017.PubMed Durak I, Yasa MH, Bektas A, et al. Mucosal antioxidant defense is not impaired in ulcerative colitis. Hepatogastroenterology. 2000;47:1015–1017.PubMed
13.
Zurück zum Zitat Tüzün A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. ClinBiochem. 2002;35:569–572. Tüzün A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. ClinBiochem. 2002;35:569–572.
14.
Zurück zum Zitat Maor I, Rainis T, Lanir A, Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn’s disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53:2208–2214.PubMedCrossRef Maor I, Rainis T, Lanir A, Lavy A. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn’s disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53:2208–2214.PubMedCrossRef
15.
Zurück zum Zitat Beltrán B, Nos P, Dasí F, et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn’s disease. Inflamm Bowel Dis. 2010;16:76–86.PubMedCrossRef Beltrán B, Nos P, Dasí F, et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn’s disease. Inflamm Bowel Dis. 2010;16:76–86.PubMedCrossRef
16.
Zurück zum Zitat Freeman HJ. Use of the Crohn’s disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008;14:4127–4130.PubMedCrossRef Freeman HJ. Use of the Crohn’s disease activity index in clinical trials of biological agents. World J Gastroenterol. 2008;14:4127–4130.PubMedCrossRef
17.
Zurück zum Zitat Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.PubMedCrossRef Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.PubMedCrossRef
18.
Zurück zum Zitat Hritcu L, Ciobica A, Gorgan L. Nicotine-induced memory impairment by increasing brain oxidative stress. Cent Eur J Biol. 2009;4:335–342.CrossRef Hritcu L, Ciobica A, Gorgan L. Nicotine-induced memory impairment by increasing brain oxidative stress. Cent Eur J Biol. 2009;4:335–342.CrossRef
19.
Zurück zum Zitat Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479:317–320.PubMedCrossRef Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479:317–320.PubMedCrossRef
20.
Zurück zum Zitat Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2010;469:6–10.PubMedCrossRef Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2010;469:6–10.PubMedCrossRef
22.
Zurück zum Zitat Pietarinen-Runtti P, Lakari E, Raivio KO, Kinnula VL. Expression of antioxidant enzymes in human inflammatory cells. Am J Physiol Cell Physiol. 2000;278:C118–C125.PubMed Pietarinen-Runtti P, Lakari E, Raivio KO, Kinnula VL. Expression of antioxidant enzymes in human inflammatory cells. Am J Physiol Cell Physiol. 2000;278:C118–C125.PubMed
23.
Zurück zum Zitat Hata Y, Kawabe T, Hiraishi H, et al. Antioxidant defenses of cultured colonic epithelial cells against reactive oxygen metabolites. Eur J Pharmacol. 1997;321:113–119.PubMedCrossRef Hata Y, Kawabe T, Hiraishi H, et al. Antioxidant defenses of cultured colonic epithelial cells against reactive oxygen metabolites. Eur J Pharmacol. 1997;321:113–119.PubMedCrossRef
24.
Zurück zum Zitat Alzoghaibi MA, Al Mofleh IA, Al-Jebreen AM. Lipid peroxides in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2007;13:187–190. Alzoghaibi MA, Al Mofleh IA, Al-Jebreen AM. Lipid peroxides in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2007;13:187–190.
25.
Zurück zum Zitat Akman T, Akarsu M, Akpinar H, Resmi H, Sezer E. Erythrocyte deformability and oxidative stress in inflammatory bowel disease. Dig Dis Sci. 2012;57:458–464.PubMedCrossRef Akman T, Akarsu M, Akpinar H, Resmi H, Sezer E. Erythrocyte deformability and oxidative stress in inflammatory bowel disease. Dig Dis Sci. 2012;57:458–464.PubMedCrossRef
26.
Zurück zum Zitat Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B. Antioxidant and immune status in active Crohn’s disease: a possible relationship. Clin Nutr. 2000;19:43–48.PubMedCrossRef Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B. Antioxidant and immune status in active Crohn’s disease: a possible relationship. Clin Nutr. 2000;19:43–48.PubMedCrossRef
27.
Zurück zum Zitat Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn’s disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis. 2000;6:77–84.PubMedCrossRef Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn’s disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis. 2000;6:77–84.PubMedCrossRef
28.
Zurück zum Zitat Hinks LJ, Inwards KD, Lloyd B, Clayton B. Reduced concentrations of selenium in mild Crohn’s disease. J Clin Pathol. 1988;41:198–201.PubMedCrossRef Hinks LJ, Inwards KD, Lloyd B, Clayton B. Reduced concentrations of selenium in mild Crohn’s disease. J Clin Pathol. 1988;41:198–201.PubMedCrossRef
29.
Zurück zum Zitat Dagli U, Balk M, Yucel D, et al. The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis. 1997;3:260–264.PubMed Dagli U, Balk M, Yucel D, et al. The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis. 1997;3:260–264.PubMed
30.
Zurück zum Zitat Tsunada S, Iwakiri R, Ootani H, Aw TY, Fujimoto K. Redox imbalance in the colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2003;38:1002–1003.PubMedCrossRef Tsunada S, Iwakiri R, Ootani H, Aw TY, Fujimoto K. Redox imbalance in the colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2003;38:1002–1003.PubMedCrossRef
31.
Zurück zum Zitat Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflam Bowel Dis. 2010;16:338–346.CrossRef Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflam Bowel Dis. 2010;16:338–346.CrossRef
32.
Zurück zum Zitat Barbosa DS, Cecchini R, El Kadri MZ, Rodríguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty-acids. Nutrition. 2003;19:837–842.PubMedCrossRef Barbosa DS, Cecchini R, El Kadri MZ, Rodríguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty-acids. Nutrition. 2003;19:837–842.PubMedCrossRef
33.
Zurück zum Zitat Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol. 2003;98:348–353.PubMed Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol. 2003;98:348–353.PubMed
34.
Zurück zum Zitat Suzuki Y, Matsumoto T, Okamoto S, Hibi T. A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. Colorectal Dis. 2008;10:931–934.PubMed Suzuki Y, Matsumoto T, Okamoto S, Hibi T. A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. Colorectal Dis. 2008;10:931–934.PubMed
Metadaten
Titel
Different Profile of Peripheral Antioxidant Enzymes and Lipid Peroxidation in Active and Non-active Inflammatory Bowel Disease Patients
verfasst von
D. Achitei
A. Ciobica
G. Balan
E. Gologan
C. Stanciu
G. Stefanescu
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2510-z

Weitere Artikel der Ausgabe 5/2013

Digestive Diseases and Sciences 5/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.